We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: AML
MedXY News
EnglishTag

AML

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies
Hematology-OncologyGVHD prophylaxisMDS

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies

By MedXY|Sep 17, 2026

A large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripher

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know
Hematology-OncologyFLT3-ITDNGS

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know

By MedXY|Aug 15, 2026

The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing acti

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia
Hematology-OncologyAMLCD276

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

By MedXY|Jul 15, 2026

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
Clinical UpdatesAMLdecitabine/cedazuridine

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

By MedXY|Jul 9, 2026

Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT
Hematology-Oncologyallo-SCTAML

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY|Jun 30, 2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable surviva

BRAF Mutations in AML: Rare, Biologically Distinct, and Linked to Poor Outcomes
Hematology-OncologyAMLBRAF mutation

BRAF Mutations in AML: Rare, Biologically Distinct, and Linked to Poor Outcomes

By MedXY|Jun 19, 2026

BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain in

S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia
Hematology-OncologyAMLfingolimod

S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia

By MedXY|Jun 4, 2026

Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationAML

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY|Jun 2, 2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY|May 27, 2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML
Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationAML

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML

By MedXY|May 18, 2026

Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement
Hematology-OncologyAMLFLT3-ITD

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement

By MedXY|May 18, 2026

Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.

Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1
Hematology-OncologyAMLFLT3-ITD

Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1

By MedXY|Apr 27, 2026

A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn’t impact overall survi

Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant
Hematology-OncologyAMLCAR T-cell therapy

Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant

By MedXY|Apr 27, 2026

VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, demonstrated acceptable safety and preliminary efficacy in relapsed/refractory AML/MDS after allogeneic HCT, with 20% overall response rate and manageable toxicities.

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

By MedXY|Mar 29, 2026

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for

Beyond Genetics: Targeting BMP and TAZ/TEAD Mechanotransduction to Reverse Chemoresistance in Acute Myeloid Leukemia
Hematology-OncologyAMLBMPR1B

Beyond Genetics: Targeting BMP and TAZ/TEAD Mechanotransduction to Reverse Chemoresistance in Acute Myeloid Leukemia

By MedXY|Mar 28, 2026

Recent research identifies BMPR1B and TAZ/TEAD as critical mechanotransduction drivers in relapsed AML. By targeting these pathways, clinicians may overcome the protective effects of bone marrow stiffening and intramedullary pressure, offer

The NSUN2-FOSB Feedforward Loop: Unlocking m5C-Mediated Survival in Acute Myeloid Leukemia
Hematology-OncologyAMLm5C メチル化

The NSUN2-FOSB Feedforward Loop: Unlocking m5C-Mediated Survival in Acute Myeloid Leukemia

By MedXY|Mar 18, 2026

Researchers identify a novel NSUN2-FOSB-BCL2L1 regulatory axis in AML that drives leukemia stem cell self-renewal through m5C RNA methylation. This pathway offers a potential therapeutic target that spares normal hematopoiesis, suggesting a

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia
Clinical UpdatesAMLAntibody-drug conjugate

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

By MedXY|Mar 18, 2026

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotox

CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis
Hematology-OncologyAMLCPX-351

CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis

By MedXY|Feb 18, 2026

A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction i

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS
Hematology-OncologyAMLHematologic Malignancies

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS

By MedXY|Jan 20, 2026

This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signa

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes
Hematology-OncologyAMLferroptosis

Metformin Triggers Ferroptosis in AML Through Lipid Remodeling: A Repurposing Opportunity for Metabolic Subtypes

By MedXY|Nov 22, 2025

A new ex vivo study shows metformin induces ROS-driven ferroptosis in acute myeloid leukemia (AML), particularly in samples with altered lipid metabolism (IDH2, FLT3 mutations). Lipidomic remodeling, CD36-mediated fatty acid uptake, and DGA

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities